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We greatly appreciated and were impressed by the review 
article by Wyszomirski et al. looking at the evidence regar-
ding the efficacy of intra-venous (IV) and intra-arterial (IA) 
thrombolysis with recombinant tissue plasminogen activator 
(rt-PA) and mechanical thrombectomy (MT) in the treatment 
of acute basilar artery occlusion (BAO) [1], and Lattanzi et 
al. who reviewed the state of current knowledge about future 
challenges of stroke management [2], as well as the response 
to the letter ‘Future challenges of stroke treatment’ written by 
Karaszewski et al. [3]. To date, only a few studies concerning 
BAO treatment with rt-PA have been published, but with no 
randomised clinical trials [1]. The treatment of acute BAO is 
still based upon consensus, clinical practice, and estimations 
of clinical benefits [2].
In relation to the articles written by Wyszomirski et al., 
Lattanzi et al. and Karaszewski et al., we would like to emp-
hasise that a similar problem concerns the treatment of spinal 
cord infarction (SCI), which accounts for 0.3–1% of all strokes 
and results in high mortality, disability, and reduced quality 
of life [4]. The most common risk factors for SCI are athero-
sclerosis, hypertension, diabetes, and cardioembolism [5]. 
Iatrogenic SCI accounts for 45% of all SCI and can be caused 
by aortic surgery (0.3–6.5%), epidural steroid injection, intra-
-aortic balloon pump, lumbar epidural catheter placement, or 
orthopaedic lumbar surgery [6, 7].
The spinal cord supply is divided into four semi-distinct 
territories: C1-T3 supplied by the vertebral arteries, T3-T7 su-
pplied by the intercostal arteries, T8 to T12 supplied by the 
artery of Adamkiewicz, and the conus supplied by a medullary 
conus artery arising from the internal iliac artery [4, 7]. A zone 
of less anastomoses is located between the T4 and T8 regions 
and may be susceptible to SCI [8]. 
In contrast to cerebral ischaemic infarction, where the 
guidelines for management and pre- and post-hospital care 
are well-established, there are no standard guidelines for 
the management of SCI, and there is no causative registered 
treatment except for acetylic acid. This is probably due to the 
low prevalence of SCI and its diverse aetiology and clinical 
presentation. In addition, to date there have been no large 
clinical trials evaluating the treatment options for SCI [9]. 
There are only some reports regarding SCI treatment with 
rt-PA, but the benefits of this therapy and its associated risks 
are unclear [10].
In response to the articles by Wyszomirski et al., Lattanzi 
et al. and Karaszewski et al., we would like to present the case 
of a patient with SCI treated off label with IV rt-PA who made 
a full recovery. A 74-year-old patient with a medical history of 
hypertension, coronary heart disease, heart infarction in 1992, 
and coronary artery bypass graft (CABG) in 2017, was admit-
ted to our Neurology Department due to lower limb weakness 
which had started two hours before admission. The neurologi-
cal examination revealed paraparesis without sensory deficit 
and sphincter disturbances (NIHSS = 6, Rankin = 4). The 
results of laboratory studies, cerebral computer tomography 
(CT) and CT-angiography, CT of the thoracic and lumbosacral 
spine, echocardiography and abdominal ultrasound all showed 
no abnormalities. Four hours after symptoms onset, the patient 
was treated with IV rt-PA, with neurological improvement in 
the form of diminished paraparesis. Cerebral CT performed 
after 24 hours was normal, but magnetic resonance imaging 
(MRI) of the spinal cord showed an infarct on the left side 
of the spinal cord extending from Th10 to Th11 segments. 
The patient was discharged from hospital with full recovery 
(NIHSS = 0, Rankin = 0).
So in relation to the articles written by Wyszomirski et 
al., Lattanzi et al. and Karaszewski et al., we would like to 
emphasise the urgent need to establish guidelines for mana-
gement, pre- and post-hospital care in SCI. Up to now, only 
a few patients with SCI have been treated with IV rt-PA, but no 
randomised clinical trials have been registered. Our case report 
shows that SCI treatment with IV rt-PA can be very effective, 
and that randomised controlled trials or large observational 
studies are required to deliver more data.
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